AbbVie Inc. ABBV Analyst Ratings

16 ratings from Wall Street analysts · latest analyst action Feb 10, 2026

Analyst Ratings
Buy Consensus target withheld — no analyst update in over 90 days showing 16 ratings
Latest analyst action Feb 10, 2026
ABBV
Resumed
2026-01-07
UBS
RatingNeutral
From
Target$240
From
Upgrade
2025-12-10
HSBC Securities
RatingBuy
FromHold
Target$265
From
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From
Target$280
From
Downgrade
2025-11-04
DZ Bank
RatingHold
FromBuy
Target$237
From
Upgrade
2025-09-17
Berenberg
RatingBuy
FromHold
Target$270
From
Resumed
2025-08-12
Piper Sandler
RatingOverweight
From
Target$231
From
Upgrade
2025-08-07
Daiwa Securities
RatingOutperform
FromNeutral
Target$214
From
Downgrade
2025-05-14
Citigroup
RatingNeutral
FromBuy
Target$205
From
Initiated
2025-04-22
Cantor Fitzgerald
RatingOverweight
From
Target$210
From
Resumed
2024-12-10
BofA Securities
RatingNeutral
From
Target$191
From
Downgrade
2024-12-05
Daiwa Securities
RatingNeutral
FromOutperform
Target$180
From
Upgrade
2024-11-22
Leerink Partners
RatingOutperform
FromMarket Perform
Target$206
From
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From
Target$205
From
Initiated
2024-10-17
Bernstein
RatingMkt Perform
From
Target$203
From
Upgrade
2024-06-05
HSBC Securities
RatingBuy
FromHold
Target$185
From
Initiated
2024-05-17
Cantor Fitzgerald
RatingOverweight
From
Target$200
From